AD/PD 2023 | Key questions for cell and gene therapy trials in Parkinson’s disease

Cell and gene therapy as a means of treating Parkinson’s disease (PD) is rapidly developing, with cell therapy clinical trials already having commenced and gene therapies starting to enter human studies. Emma Lane, PhD, Cardiff University, Cardiff, UK, discusses the importance of creating a trial design that captures the long-term safety and adverse events adequately and meaningfully. Dr Lane explains a recent trial with cell therapy where graft-induced dyskinesias as a side effect were very obvious in some patients, but only noted through retrospective video analysis in others. This example highlights the importance of factoring in how these side effects are captured and monitored to truly evaluate the risk and severity of them and use that information to balance our understanding of the therapy benefits. This interview took place at the AD/PD™ 2023 congress in Gothenburg, Sweden.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.